You are currently browsing the archives for the Antitrust category.

Robin Feldman on Drug Manufacturers’ Abuse of the Citizen-Petition Process

Published on: Author: Jaime King

Soaring healthcare prices currently threaten the viability of our healthcare system and the overall economy. U.S. healthcare spending, both per capita and as a percentage of GDP, far outpaces spending by any other high-income country, without corresponding increases in quality or access to care. Pharmaceutical drug prices, a component of overall healthcare spending, have dramatically… Continue reading →

Jaime King on the Anti-Competitive Potential of Cross-Market Mergers in Health Care

Published on: Author: Robin Feldman

What drives health care costs ever higher? Consolidation may be playing a key role. In this context, Professor Jaime King’s contribution to the St. Louis University Annual Health Law Symposium, “The Anti-Competitive Potential of Cross-Market Mergers in Health Care” (coauthored with Erin C. Fuse Brown), is a clarion call for antitrust authorities to consider seriously… Continue reading →